The accuracy and robustness of plasma biomarker models for amyloid PET positivity
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1758-9193
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
The accuracy and robustness of plasma biomarker models for amyloid PET positivity ; volume:14 ; number:1 ; day:7 ; month:2 ; year:2022 ; pages:1-11 ; date:12.2022
Alzheimer's research & therapy ; 14, Heft 1 (7.2.2022), 1-11, 12.2022
- Urheber
-
Benedet, Andréa L.
Brum, Wagner S.
Hansson, Oskar
Karikari, Thomas K.
Zimmer, Eduardo R.
Zetterberg, Henrik
Blennow, Kaj
Ashton, Nicholas J.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13195-021-00942-0
- URN
-
urn:nbn:de:101:1-2022051420244439187428
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:32 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Benedet, Andréa L.
- Brum, Wagner S.
- Hansson, Oskar
- Karikari, Thomas K.
- Zimmer, Eduardo R.
- Zetterberg, Henrik
- Blennow, Kaj
- Ashton, Nicholas J.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Fluid biomarkers in Alzheimer’s disease – current concepts
Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders
Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease
Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment
Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease
Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias
Publisher Correction: Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies
Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies
Cerebral Aβ deposition precedes reduced cerebrospinal fluid and serum Aβ42/Aβ40 ratios in the App NL−F/NL−F knock-in mouse model of Alzheimer’s disease
Neuroligin-1 in brain and CSF of neurodegenerative disorders: investigation for synaptic biomarkers
Salivary Biomarkers for Alzheimer’s Disease and Related Disorders
Fluid biomarkers in Alzheimer’s disease – current concepts
Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders
Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease
Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment
Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease
Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias
Publisher Correction: Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies
Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies
Cerebral Aβ deposition precedes reduced cerebrospinal fluid and serum Aβ42/Aβ40 ratios in the App NL−F/NL−F knock-in mouse model of Alzheimer’s disease
Neuroligin-1 in brain and CSF of neurodegenerative disorders: investigation for synaptic biomarkers
Salivary Biomarkers for Alzheimer’s Disease and Related Disorders
Fluid biomarkers in Alzheimer’s disease – current concepts
Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders
Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease
Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment
Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease
Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias
Publisher Correction: Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies
Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies
Cerebral Aβ deposition precedes reduced cerebrospinal fluid and serum Aβ42/Aβ40 ratios in the App NL−F/NL−F knock-in mouse model of Alzheimer’s disease
Neuroligin-1 in brain and CSF of neurodegenerative disorders: investigation for synaptic biomarkers